Visx
This article was originally published in The Gray Sheet
Executive Summary
Financier Carl Icahn forgoes earlier plan to elect a rival slate of directors to the firm's board at the May 2002 annual meeting (1"The Gray Sheet" Nov. 26, 2001, p. 30). In a recent 13D filing with the Securities & Exchange Commission, Icahn maintained that depending upon market conditions, he may acquire or dispose of additional shares. Icahn previously proposed to acquire Visx for $32 per share in a hostile takeover bid last April...
You may also be interested in...
Icahn Renews Effort To Replace Visx Board At Next Shareholder Meeting
Financier Carl Icahn appears to have abandoned his $32 a share cash tender offer for Visx in favor of electing a rival slate of directors to the firm's board, a strategy that in the past has failed
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.